[go: up one dir, main page]

CU24596B1 - Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes - Google Patents

Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes

Info

Publication number
CU24596B1
CU24596B1 CU2019000078A CU20190078A CU24596B1 CU 24596 B1 CU24596 B1 CU 24596B1 CU 2019000078 A CU2019000078 A CU 2019000078A CU 20190078 A CU20190078 A CU 20190078A CU 24596 B1 CU24596 B1 CU 24596B1
Authority
CU
Cuba
Prior art keywords
diabetes
treatment
peptides obtained
insulin
useful
Prior art date
Application number
CU2019000078A
Other languages
English (en)
Other versions
CU20190078A7 (es
Inventor
Vincent Carlier
Jean-Marie Saint-Remy
Elst Luc Vander
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of CU20190078A7 publication Critical patent/CU20190078A7/es
Publication of CU24596B1 publication Critical patent/CU24596B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

<p>La presente invención se refiere a péptidos sintéticos inmunogénicos, obtenidos a partir de insulina con longitud entre 12 a 50 aminoácidos tales como HCPYCSLQPLALEGSLQKRG, útiles en el tratamiento de la diabetes tipo 1. Los péptidos de la presente invención generan células TCD4+ citolíticas con una alta producción de IFN-gamma y sFasL, también incrementan la producción de granzima B en dichas células TCD4+.</p>
CU2019000078A 2017-03-09 2018-03-06 Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes CU24596B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (2)

Publication Number Publication Date
CU20190078A7 CU20190078A7 (es) 2020-04-02
CU24596B1 true CU24596B1 (es) 2022-05-11

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000078A CU24596B1 (es) 2017-03-09 2018-03-06 Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes

Country Status (21)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CA (1) CA3051518A1 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926004A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in allergic and autoimmune disorders
PL2249864T3 (pl) * 2008-02-14 2016-11-30 Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynniki
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
BR112019018616A2 (pt) * 2017-03-09 2020-04-28 Imcyse Sa peptídeos e métodos para o tratamento de diabetes
CA3163178A1 (en) * 2019-11-27 2021-06-03 Imcyse Sa Methods for stratifying diabetes patients
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
AU2021267369A1 (en) 2020-05-06 2022-12-15 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
CN115867567A (zh) * 2020-05-06 2023-03-28 易姆赛斯股份公司 具有新氧化还原酶基序的免疫原性肽
AU2022286630A1 (en) 2021-06-01 2023-12-07 Imcyse Sa Improved methods of treatment using immunogenic peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316610A (zh) * 2005-09-22 2008-12-03 艾润·R·科恩 T细胞受体恒定区的免疫原性片段及其衍生的肽
CA2926004A1 (en) * 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in allergic and autoimmune disorders
US20120009678A1 (en) 2008-02-14 2012-01-12 Jean-Marie Saint-Remy Immunotherapy targeting intracellular pathogens
PL2249864T3 (pl) 2008-02-14 2016-11-30 Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynniki
CA2715517C (en) 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP2623124A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
AU2009214041A1 (en) * 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CA2792174C (en) 2010-03-29 2019-09-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
BR112019018616A2 (pt) * 2017-03-09 2020-04-28 Imcyse Sa peptídeos e métodos para o tratamento de diabetes
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心

Also Published As

Publication number Publication date
RU2019126232A (ru) 2021-04-10
WO2018162498A1 (en) 2018-09-13
US20240092843A1 (en) 2024-03-21
US11760782B2 (en) 2023-09-19
IL268874A (en) 2019-10-31
ZA201905851B (en) 2021-04-28
RU2761653C2 (ru) 2021-12-13
US20190352348A1 (en) 2019-11-21
JP2022125216A (ja) 2022-08-26
KR20190126798A (ko) 2019-11-12
JP7102430B2 (ja) 2022-07-19
JP2020509067A (ja) 2020-03-26
BR112019018616A2 (pt) 2020-04-28
EP3592765A1 (en) 2020-01-15
IL268874B2 (en) 2023-09-01
AU2018229741B2 (en) 2021-09-02
NZ755744A (en) 2023-07-28
PH12019502036A1 (en) 2020-06-15
US11407795B2 (en) 2022-08-09
RU2019126232A3 (es) 2021-06-01
MY192295A (en) 2022-08-17
CN110536898B (zh) 2023-09-08
SA519410007B1 (ar) 2023-02-16
CU20190078A7 (es) 2020-04-02
MX2019010558A (es) 2019-10-21
SG11201908275XA (en) 2019-10-30
US20220411476A1 (en) 2022-12-29
CN110536898A (zh) 2019-12-03
US20200407406A1 (en) 2020-12-31
AU2018229741A1 (en) 2019-08-15
PE20191529A1 (es) 2019-10-23
CA3051518A1 (en) 2018-09-13
AU2021277735A1 (en) 2021-12-23
IL268874B1 (en) 2023-05-01
CO2019009080A2 (es) 2019-08-30
US10808016B2 (en) 2020-10-20

Similar Documents

Publication Publication Date Title
CU24596B1 (es) Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
MX377804B (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CL2016001405A1 (es) A peptide mixture
MX2016006990A (es) Peptidos autoensamblables, peptidomimeticos y conjugados peptidicos como bloques de construccion para la biofabricacion e impresion.
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
MY195167A (en) Modified Nucleotide Linkers
EA201592093A1 (ru) Композиции и способы модулирования экспрессии hbv и ttr
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
MX2016008249A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
WO2016014342A3 (en) Ang-(1-7) derviative oligopeptides and methods for using and producing the same
MX2021001545A (es) Péptidos penetrantes celulares.
MX2014014662A (es) Manufactura de degarelix.
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
CO2019012871A2 (es) Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida
MX2018007298A (es) Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa.
MX2019012083A (es) Nueva vacuna de peptidos contra la pcsk9.
MX384529B (es) Producto cosmetico con propiedades reparadoras del adn.
MX2024002130A (es) Metodos y composiciones para mejorar la expresion de proteinas recombinantes.
AR099811A1 (es) Microorganismos con una productividad de aminoácidos l mejorada y proceso para producir aminoácidos l
WO2018152446A3 (en) Cell-penetrating atf5 polypeptides and uses thereof